MediPharm Labs Corp., a pharmaceutical company specializing in precision-based cannabinoids, today announced that it has appointed experienced Pharma and Med Tech executive David Pidduck as Chief Executive Officer and Director of the Company. Mr. Pidduck replaces outgoing CEO and Director Bryan Howcroft, who is stepping down for personal reasons, effective today.
Mr. Pidduck brings more than 20 years of proven senior leadership experience to MediPharm, including serving as President and CEO of a Canadian pharmaceutical company, where he was also a member of the board of directors.
Chris Taves, Chairman of the Board commented, "We are very pleased to welcome David Pidduck to MediPharm. The Company continues to make progress building its sales pipeline both in Canada and internationally, driving toward consistent revenue growth and profitability."
David Pidduck, incoming CEO added, "I have watched the development of the medical cannabinoid industry over the past several years with great interest from my vantage point within the Pharma sector. Though the industry is still developing, cannabinoid research interest continues to grow, and I believe we may be approaching an inflection point where cannabinoids will become a larger focus for traditional Pharma. Medical cannabinoid companies are not created equal. In MediPharm, I see one of the very few organizations globally that has the required sophistication to both operate within a stringent Pharma environment, and scale rapidly to capitalize on this growth opportunity. I look forward to contributing my experience in business and corporate development to the team's current efforts, with a focus on orienting the Company toward both consistent organic growth and accretive M&A activities to drive revenue growth, profitability and value for all stakeholders."
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.